I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
In our roundup this week, Alzheimer’s disease is in the news, thanks to billionaire Bill Gates and his personal pledge of $100 million toward R&D. That could equal the amount one... Read more »
The researchers and doctors at Seattle Children’s are embarking upon a complicated quest, involving multiple clinical studies of cutting-edge CAR-T cell therapies, to help kids and young adults with an aggressive... Read more »
One of biotech’s richest private companies, Denali Therapeutics, has set its sights on an IPO to push ahead with treatments for Alzheimer’s and other confounding brain diseases.
When five patients with a difficult type of leukemia died last year in a clinical trial run by Juno Therapeutics, it was a big setback for the Seattle biotech and its... Read more »
The White House and the FDA turned the spotlight on the nation’s opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded approvals, but bad earnings news from Celgene and Biogen... Read more »
As the quest to find treatments for Alzheimer’s disease keeps crashing against rocks, a group of researchers in the field want their peers to pay more attention to the part of... Read more »
For the second time in two months, remarkable recoveries from desperate cases of cancer have led to early approval of a cutting-edge therapy called CAR-T, which is made from a patient’s... Read more »
In advance of an anticipated Senate hearing on drug prices, President Donald Trump once again denounced drug companies as “getting away with murder.” The first time he did so, using the... Read more »
Cells within a single tumor can have a variety of genetic fingerprints. Understanding that variety is likely a key to fighting cancer in the near future.
A new biotech firm has... Read more »
In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through... Read more »
In the run-up to a key vote on an experimental gene therapy, the FDA raised no major flags about the drug’s track record but said its long-term effect remains an open... Read more »
The 2017 Nobel Prizes with a biomedical bent were announced this week. Three researchers shared the physiology and medicine prize for their work shining light on the circadian rhythms that govern... Read more »
With its first clinical trial possibly just months away, one of the leading biotech firms using CRISPR-Cas9 gene editing technology to make drugs is turning to a new CEO.
CRISPR Therapeutics... Read more »
Another high-profile attempt to produce an Alzheimer’s treatment has failed.
[Corrected, 10/10/17, 2 p.m. ET. See below.] It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. At three... Read more »
[Corrected 12:20pm ET; see below.] The national debate over the high cost of healthcare, with prescription drugs at the center, resonates from the chambers of Congress to every American’s pocketbook. And... Read more »
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.